20160128 EGA Regulatory and Scientific Affairs Conferenc

Oncology, the new era for biosimilar medicines

8 September 2017

With more than 10 years of positive experience and 700 […]

Read more

Value Added Medicines: Time to adjust the HTA Decision Frameworks for more patient-centric innovation

5 September 2017

A new study “Value Added Medicines: Time to Adjust the […]

Read more

Latest Data Shows the Need to Promote Biosimilar and Value Added Medicines for Better Health

16 June 2017

Biosimilar medicines are transforming treatment by enabling better access to […]

Read more

62% of Medicines Dispensed in Europe are Generic, according to IMS New Data

15 June 2017

Pharmaceutical industry leaders and key stakeholders from the generic, biosimilar […]

Read more

EU Semester Country Specific Recommendations: More Efficient Medicine Policies Needed for Patient Access

23 May 2017

The European Semester Country Specific Recommendations show that healthcare systems […]

Read more

New Alliance to Drive and Measure Industry Progress to Curb Antimicrobial Resistance

18 May 2017

Speaking at the B20 Health Conference in Berlin, IFPMA Director-General […]

Read more

Biosimilar Medicines Opportunity: Dramatic Increase in Patient Access across Europe

9 May 2017

The new report on The Impact of Biosimilar Competition in […]

Read more

Industry Welcomes the 3rd European Commission Workshop on Biosimilar Medicines

5 May 2017

The European pharmaceutical industry welcomes the 3rd workshop on access […]

Read more

Over 100 Participants Explore Opportunities to Ensure Universal Access to Health

27 April 2017

Over 100 participants explored different ways and opportunities to ensure […]

Read more

22nd EAHP Conference in Cannes

25 March 2017

A special satellite  symposium was organized on “Value added medicines […]

Read more

Subscribe to our newsletter